19 Feb 2020 07:00
19 February 2020 07:00 GMT
Â
Â
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
Â
AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demaré, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demaré purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £73.13 per Share.
Â
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
Â
1  | Details of the person discharging managerial responsibilities / person closely associated  | |||||
a)  | Name   | Michel Demaré | ||||
2  | Reason for the notification  | |||||
a)  | Position/status   | Non-Executive Director | ||||
b)  | Initial notification /Amendment   | Initial notification | ||||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | |||||
a)  | Name   | AstraZeneca PLC | ||||
b) Â | LEI Â Â | PY6ZZQWO2IZFZC3IOL08 | ||||
4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   | |||||
a)  | Description of the financial instrument, type of instrument  Identification code   | Ordinary Shares of US$0.25 each in AstraZeneca PLC   GB0009895292  | ||||
b)  | Nature of the transaction   | Share purchase | ||||
c) Â | Price(s) and volume(s) Â Â | Â
  | ||||
d)  | Aggregated information   - Aggregated volume   - Price   | Not applicable - single transaction  | ||||
e)  | Date of the transaction   | 17 February 2020 | ||||
f)  | Place of the transaction   | XLON |
Â
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
Â
 Media Relations |  |  |
Gonzalo Viña |  | +44 203 749 5916 |
Rob Skelding | Oncology | +44 203 749 5821 |
Rebecca Einhorn | Oncology | +1 301 518 4122 |
Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
Jennifer Hursit | Other | +44 203Â 749 5762 |
Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
Michele Meixell | US | +1 302 885 2677 |
 |  |  |
Investor Relations | Â | Â |
Thomas Kudsk Larsen | Â | +44 203 749 5712 |
Henry Wheeler | Oncology | +44 203 749 5797 |
Christer Gruvris | BioPharmaceuticals (cardiovascular; metabolism) | +44 203 749 5711 |
Nick Stone | BioPharmaceuticals (respiratory; renal) | +44 203 749 5716 |
Josie Afolabi | Other medicines | +44 203 749 5631 |
Craig Marks | Finance, fixed income | +44 7881 615 764 |
Jennifer Kretzmann | Corporate access, retail investors | +44 203 749 5824 |
US toll-free | Â | +1 866 381 72 77 |
Adrian KempCompany SecretaryAstraZeneca PLC